ScholarWorks@Korea University College of Medicine: Kang, Eun Joo

Detailed Information

Kang, Eun Joo (강은주)

Guro Hospital (Department of Medical Oncology and Hematology, Guro Hospital)

Research Area

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Prognosis:4||prognosis:3||chemotherapy:3||Chemotherapy:3||nonsmall cell lung cancer:3||Pediatric Palliative Care:2||Prognostic Disclosure to Children:2||immunotherapy:2||Prognostic factor:2||Molecular targeted therapy:2||cellfree DNA:2||Small cell lung cancer:2||Republic of Korea:2||PDL1:2||Biomarkers:2||head and neck cancer:2||Surgery:2||Pediatric Advance Care Planning:2||breast cancer:2||Chronic Conditions:1||Cisplatin:1||Clinical trial:1||Communication:1||Comorbidity:1||Complications:1||Durvalumab:1||End of Life Care:1||Endoflife:1||Epidermal growth factor receptor:1||FOLFIRI:1||Firstline chemotherapy:1||Gastric cancer:1||Good death:1||HER2:1||HIV/AIDS:1||Head and neck neoplasms:1||Heart:1||Heart neoplasms:1||Hematopoietic stem cell transplantation:1||Highthroughput nucleotide sequencing:1||Hyponatremia:1||Implantable venous access port:1||Induction chemotherapy:1||Inflammation:1||Irinotecan:1||Khorana score:1||Left ventricle∙Pseudoaneurysm∙Myocardial infarction:1||Liver:1||Locally advanced head and neck cancer:1||Locally advanced head and neck squamous cell carcinoma:1||Metabolic tumor volume:1||Molecular:1||Multidisciplinary treatment:1||Neoplasm:1||Neoplasms:1||Neurological Conditions:1||Nextgeneration sequencing:1||Nonsmall cell lung cancer:1||Nonsmall cell lung carcinoma:1||Nonsmallcell lung carcinoma:1||Oral health:1||Osteosarcoma:1||PAS:1||PDL2:1||Pancreatic cancer:1||Pancreatic neoplasms:1||Pathology:1||Pemetrexed:1||Platelet function analyzer:1||Postprogression survival:1||Precision medicine:1||Predictive value:1||Primary Pericardial Mesothelioma:1||Prognostic factors:1||Prognostic marker:1||Risk:1||Risk factor:1||Salivary duct carcinoma (SDC) is a rare:1||Salivary gland cancer:1||Screening test:1||Secondline chemotherapy:1||Singleincision technique:1||Skeletalrelated event:1||Squamous cell carcinoma:1||Squamous cell carcinoma of the head and neck:1||Strategy:1||Subsequent treatment:1||Targetable gene alteration:1||Therapeutics:1||Thiamine:1||Thirdline chemotherapy:1||Tooth loss:1||Total lesion glycolysis:1||Toxocariasis:1||Urinary bladder:1||Venous thromboembolism:1||Visceral larva migrans:1||Wernicke’s encephalopathy:1||Wild type:1||YKL40:1||active euthanasia:1||active pain control:1||adenoid cystic carcinoma:1||adjuvant:1||advance directives:1||aggressive tumor. Androgen deprivation therapy (ADT) has been shown to have beneficial effects on SDCexpressing androgen receptors (ARs). A 69yearold male with a right neck mass presented to our clinic. Computed tomography (CT) of the neck revealed a mass (6 cm diameter) on the right parotid gland:1||and enlarged lymph nodes. Examination of a needle biopsy sample identified SDCexpressing ARs. We performed total parotidectomy with bilateral neck dissection and concurrent postoperative chemoradiotherapy (total 66 Gy) with cisplatin (35 mg/m2):1||artificial intelligenceanalysis:1||attitudes toward death:1||axitinib:1||biologically aggressive:1||brain metastasis:1||breast neoplasm:1||cancer:1||cancer patients:1||cardiovascular disease:1||caregiver:1||cellfree DNA concentration:1||chest CT indicated recurrence in the right axilla. We initiated ADT with bicalutamide and leuprolide. Five months later:1||cisplatin:1||clinical outcome:1||clinicians should consider ADT in recurrent or metastatic SDC of ARs.:1||comorbidity:1||coronavirus disease 2019:1||decisionmaking:1||discontinuation:1||disease free survival:1||docetaxelPM:1||duration of treatment:1||early palliative care:1||elderly:1||epidermal growth factor receptor:1||estrogen receptor:1||everolimus:1||exemestane:1||followed by another two cycles of chemotherapy (cisplatin 60 mg/m2:1||gender:1||head and neck cancers:1||however:1||hydroxymethylglutarylCoA reductase inhibitors:1||immune cell:1||immune checkpoint inhibitor:1||immune checkpoint inhibitors:1||isolated locoregional recurrence:1||life support care:1||locally advanced head and neck squamous cell carcinoma:1||longterm survival:1||lung cancer:1||lung function:1||mRNA expression:1||malignant mesothelioma:1||malignant salivary gland tumors:1||metastatic extramammary Paget's disease:1||missense mutation:1||modes of death:1||molecular subtype:1||molecular targeted therapy:1||multiplex polymerase chain reaction:1||mutations:1||nintedanib:1||nonsmall cell lung carcinoma:1||nonsmallcell lung:1||nonsmallcell lung cancer:1||nonsmallcell lung carcinoma:1||nonsmall cell lung cancer:1||obstructive lung disease:1||overall survival:1||passive euthanasia:1||patient:1||pemetrexed:1||perception:1||pericardium:1||predictive biomarker:1||prognostic factors:1||prognostic indicator:1||prognostic value:1||progressionfree survival:1||proton pump inhibitors:1||pulmonary sarcomatoid carcinoma:1||relapsefree survival:1||risk:1||safety:1||salivary duct carcinoma:1||salivary gland cancer:1||screening:1||secondline treatment:1||sequencing:1||stroke:1||survival:1||survivorship:1||terminal care:1||the axillar tumor tissue had almost disappeared. Our case demonstrates that ADT is effective for SDC of ARs. Therefore:1||trastuzumab:1||trastuzumabpkrb:1||tremelimumab:1||tumorinfiltrating lymphocyte:1||tumorinfiltrating lymphocytes:1||vaccine:1||vascular endothelial growth factor receptor (VEGFR):1||골육종:1||바이오마커:1||비소세포폐암:1||심장:1||심장종양:1||5 FU 750 mg/m2). Posttreatment neck CT indicated that no residual tumor tissue remained:1||표적 치료:1||ALDH1:1||Advance care planning:1||Advanced lung cancer:1||Aged:1||Androgen receptor antagonist:1||Androgen receptors:1||Attitude:1||Attitudes toward death:1||Axillary vein:1||Biliary tract cancer:1||Bleeding:1||Bone metastases:1||Breast cancer:1||CTLA4:1||Cancer:1||Carcinoma:1||Cardiac Tamponade:1||Cellfree nucleic acids quantification:1||

STATISTICS: Total View :12,710,872; Today View :9,549

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE